Concepedia

Lars Wallentin

LW

7

Publications

1.2K

Citations

7

H-Index

1997

Active since

Affiliations

Uppsala University Hospital(Current)

Uppsala University

Lars Wallentin is an author at Uppsala University Hospital specializing in cardiovascular disease, atherosclerosis, and heparins.

Top concepts

Publications per year

1997–2013

7

Publications

7

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Lars Wallentin, Christoph Varenhorst, Stefan James et al. · European Heart Journal · 2007 · 455 citations · Full text

Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)

Eva Swahn, Lars Wallentin · The American Journal of Cardiology · 1997 · 356 citations

, , +11

Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction

Tibor Kempf, E. Bjorklund, S.‐O. Olofsson et al. · European Heart Journal · 2007 · 228 citations · Full text

Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease

Christoph arenhorst, Stefan James, John T. Brandt et al. · Thrombosis and Haemostasis · 2008 · 73 citations

Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction—the ASSENT Plus study

Lars Wallentin · European Heart Journal · 2003 · 55 citations · Full text

Rows per page

1–5 of 7